BCG 019
Alternative Names: BCG-019Latest Information Update: 08 Jul 2024
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jun 2024 BCG 019 is available for licensing as of 17 Jun 2024. https://www.biocytogen.jp/technology/detail/bispecific-ADC.html (Beijing Biocytogen website; June 2024)
- 05 Apr 2024 Preclinical trials in Cancer in China (Parenteral) prior to April 2024
- 05 Apr 2024 Pharmacodynamics data from the preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024)